IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

CASAS, D, J ALCEDO, M LAFUENTE, LÓPEZ, A PÉREZ-AISA, M PAVONI, SARACINO, B TEPES, L JONAITIS, M CASTRO-FERNÁNDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, I VOYNOVAN, L BUJANDA, A J LUCENDO, N Brglez JURECIC, M DENKOVSKI, PHULL, L RODRIGO, A LANAS, MARTÍNEZ-DOMÍNGUEZ, HUGUET, BORDIN, A GASBARRINI, J KUPCINSKAS, G BABAYEVA, O GRIDNYEV, M LEJA, T ROKKAS, R MARCOS-PINTO, F LERANG, D BOLTIN, V PAPP, A TONKIĆ, SMITH, H SIMSEK, M VENERITO, L BOYANOVA, V MILIVOJEVIC, Lumír KUNOVSKÝ, T MATYSIAK-BUDNIK, W MARLICZ, M DOULBERIS, A CANO-CATALÀ, L HERNÁNDEZ, L MOREIRA, NYSSEN, F MEGRAUD, MORAIN and GISBERT. IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG). In 31st United European Gastroenterology Week 2023. 2023. ISSN 2050-6406.

Basic information

• Original name: IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
• Authors: CASAS, D, J ALCEDO, M LAFUENTE, LÓPEZ, A PÉREZ-AISA, M PAVONI, SARACINO, B TEPES, L JONAITIS, M CASTRO-FERNÁNDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, I VOYNOVAN, L BUJANDA, A J LUCENDO, N Brglez JURECIC, M DENKOVSKI, PHULL, L RODRIGO, A LANAS, MARTÍNEZ-DOMÍNGUEZ, HUGUET, BORDIN, A GASBARRINI, J KUPCINSKAS, G BABAYEVA, O GRIDNYEV, M LEJA, T ROKKAS, R MARCOS-PINTO, F LERANG, D BOLTIN, V PAPP, A TONKIĆ, SMITH, H SIMSEK, M VENERITO, L BOYANOVA, V MILIVOJEVIC, Lumír KUNOVSKÝ, T MATYSIAK-BUDNIK, W MARLICZ, M DOULBERIS, A CANO-CATALÀ, L HERNÁNDEZ, L MOREIRA, NYSSEN, F MEGRAUD, MORAIN and GISBERT.
• Edition: 31st United European Gastroenterology Week 2023, 2023.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 6.000 in 2022
• Organization unit: Faculty of Medicine
• ISSN: 2050-6406

Abstract

Aims & Methods: Aims: To assess the usefulness of PB use in improving the safety of eradication therapies used in Europe. Methods: Prospective, multicentre, non-interventional registry (HpEuReg) of the clinical practice of European gastroenterologists. Data were collected in an e-CRD in AEG-REDCap from 2013 to 2021. Information was included from countries with at least 30 cases undergoing eradication therapy and at least 1 with associated PB, with controls being patients without PB. AEs were categorised as mild, moderate and severe. Results were grouped by region. A modified intention-to treat analysis and a logistic regression model, considering age, sex, duration and regimen of eradication treatment, PPI dose and adherence were performed. Results: 36,699 patients were included; 8,233 (22%) treated with PB. Multiple PB formulations were used, including 9 genera and 32 species. In the PB group the rate of overall AEs was higher (25% vs 22%, p<0.0001), but the rate of severe AEs was lower (1.9% vs 1.1%, p<0.0001). The duration of AE’s was shorter in the PB group (6.4 vs 8.2 days, p<0.0001). The logistic regression model was applied to data from the Central European region as it has the highest frequency of PB use and, therefore, the lowest risk of prescription driven by expected AEs. In this model, PB use was associated with a lower incidence of both global and severe AEs. In terms of genus, with Bifidobacterium the incidence of at least one AE and that of severe AEs was lower ( p=0.0019 and p<0.001, respectively), while Lactobacillus only had benefit for the incidence of severe AEs associated with triple therapy ( p=0.0278) and Bacillus showed inconsistent results. Conclusion: The use of PB was associated with a lower incidence of AEs, as well as shorter duration and severity of AEs. The genus Bifidobacterium may be the most useful in the prevention of AEs.